Abstract
Crohn's disease (CD) is a chronic relapsing-remitting inflammatory bowel disorder with variable disease expressions, giving rise to multiple complications like abdominal discomfort, diarrhea, fever, anemia and weight loss. CD can affect any part of the digestive track from the mouth to the perianal region and up to 65% of patients may have CD affecting the small intestine. Infliximab (IFX) is an anti-tumour necrosis factor (TNF)-α antibody, which has shown efficacy in patients with CD. Further, given its efficacy in active CD, IFX has been reported to be effective as maintenance therapy to sustain remission. However, examinations of endoscopic images indicate that during maintenance IFX, complete mucosal healing is not achieved and that disease activity continues including the formation of intestinal strictures.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call